A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial
AsherBio
Updated clinical results and associated biomarkers from an ongoing phase 1 study of FX-909, a first-in-class peroxisome proliferator-activated receptor gamma (PPARG) inhibitor, in patients (pts) with advanced urothelial carcinoma (adv UC) 2026 ASCO Genitourinary Cancers Symposium
AsherBio
Phase 1 Clinical Data Show FX-909, a First-in-Class Oral PPARG Inhibitor, Drives Immune Modulation and Pro-Inflammatory Cytokine Induction in IO-Experienced Patients with Advanced Urothelial Carcinoma
AsherBio
Safety and Clinical Activity of FX-909, a First-in-Class Oral Small Molecule Inhibitor of Peroxisome Proliferator-Activated Receptor Gamma (PPARG), the Master Regulator of Luminal Lineage, in Patients with Advanced Urothelial Carcinoma
AsherBio
Webinar Presentation of FX-909 Phase 1 Part A Data in Advanced Solid Malignancies Including Advanced Urothelial Carcinoma
AsherBio
FX-909 Phase 1 Part A Data in Advanced Solid Malignancies Including Advanced Urothelial Carcinoma
AsherBio
PPARG Protein Expression in Advanced Urothelial Carcinoma May Provide a Precision Approach to Potentially Select for Response to FX-909, a First-in-Class PPARG-Targeting Agent
AsherBio
Genomic peroxisome proliferator-activated receptor gamma (PPARG) study: A sponsored testing program to identify patients harboring genetic alterations in advanced UC in support of the FX-909 Phase 1 study
AsherBio
PPARG-High Circulating Monocytes Exhibit An Immunosuppressive Phenotype In Urothelial Cancer Patients Treated with Anti-PD1
AsherBio
A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma